Literature DB >> 18983858

The prostate transglutaminase (TGase-4, TGaseP) regulates the interaction of prostate cancer and vascular endothelial cells, a potential role for the ROCK pathway.

Wen G Jiang1, Richard J Ablin, Howard G Kynaston, Malcolm D Mason.   

Abstract

Prostate transglutaminase (TGase-4 or TGaseP) is an enzyme that is uniquely expressed in prostate tissues. The function of the TGase, implicated in the cell-matrix, is yet to be fully established. In the present study, we investigated the role of TGase-4 in tumor-endothelial cell interactions, by creating a panel of prostate cancer cell lines that have different expression profiles of human TGase-4. Here, we report that prostate cancer cells PC-3, when over-expressing TGase-4 (PC-3(TGase4exp)) increased their ability to adhere to quiescent and activated (by hepatocyte growth factor) endothelial cells. In contrast, the prostate cancer cell CAHPV-10, which expressed high levels of TGase-4, reduced the adhesiveness to the endothelial cells after TGase-4 expression was knocked down. By using frequency based electric cell impedance sensing, we found that TGase-4 mediated adhesion resulted in a change in impedance at low frequency (400 Hz), indicating a paracellular pathway disruption. The study further showed that expression of TGase-4 rendered the cells to exert regulation of endothelial interaction by bypassing the ROCK pathway. It is therefore concluded, that TGase-4 plays a pivotal role in the interaction between endothelial cells and prostate cancer cells, an action which is independent of the ROCK pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18983858     DOI: 10.1016/j.mvr.2008.09.010

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  12 in total

1.  The role of transglutaminases in the pathophysiology of prostate cancer.

Authors:  R J Ablin; W G Jiang
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

2.  Differential alternative splicing of human transglutaminase 4 in benign prostate hyperplasia and prostate cancer.

Authors:  Sung-Yup Cho; Kyungho Choi; Ju-Hong Jeon; Chai-Wan Kim; Dong-Myung Shin; Jong Bouk Lee; Sang Eun Lee; Choung-Soo Kim; Jeong-Soo Park; Eui Man Jeong; Gi-Yong Jang; Kye-Yong Song; In-Gyu Kim
Journal:  Exp Mol Med       Date:  2010-04-30       Impact factor: 8.718

Review 3.  Transglutaminases: part I-origins, sources, and biotechnological characteristics.

Authors:  Lovaine Duarte; Carla Roberta Matte; Cristiano Valim Bizarro; Marco Antônio Záchia Ayub
Journal:  World J Microbiol Biotechnol       Date:  2020-01-02       Impact factor: 3.312

4.  Multi-omics Biomarker Pipeline Reveals Elevated Levels of Protein-glutamine Gamma-glutamyltransferase 4 in Seminal Plasma of Prostate Cancer Patients.

Authors:  Andrei P Drabovich; Punit Saraon; Mikalai Drabovich; Theano D Karakosta; Apostolos Dimitromanolakis; M Eric Hyndman; Keith Jarvi; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2019-06-27       Impact factor: 5.911

5.  Activated leukocyte cell adhesion molecule (ALCAM)/CD166 in pancreatic cancer, a pivotal link to clinical outcome and vascular embolism.

Authors:  Yiming Yang; Andrew J Sanders; Fiona Ruge; Xuefei Dong; Yuxin Cui; Qing Ping Dou; Shuqin Jia; Chunyi Hao; Jiafu Ji; Wen G Jiang
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

6.  Changes in proteomic profiles in different prostate lobes of male rats throughout growth and development and aging stages of the life span.

Authors:  Arunangshu Das; James D Bortner; Cesar A Aliaga; Aaron Baker; Anne Stanley; Bruce A Stanley; Matthew Kaag; John P Richie; Karam El-Bayoumy
Journal:  Prostate       Date:  2012-08-21       Impact factor: 4.104

7.  Overexpression of transglutaminase 4 and prostate cancer progression: a potential predictor of less favourable outcomes.

Authors:  Zhi Cao; Yang Wang; Zhi-Yong Liu; Zhen-Sheng Zhang; Shan-Cheng Ren; Yong-Wei Yu; Meng Qiao; Bei-Bei Zhai; Ying-Hao Sun
Journal:  Asian J Androl       Date:  2013-08-26       Impact factor: 3.285

8.  Prostate transglutaminase (TGase-4) antagonizes the anti-tumour action of MDA-7/IL-24 in prostate cancer.

Authors:  Richard J Ablin; Howard G Kynaston; Malcolm D Mason; Wen G Jiang
Journal:  J Transl Med       Date:  2011-04-28       Impact factor: 5.531

9.  YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion.

Authors:  Said Rahim; Elspeth M Beauchamp; Yali Kong; Milton L Brown; Jeffrey A Toretsky; Aykut Üren
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

10.  Prostate transglutaminase (TGase-4, TGaseP) enhances the adhesion of prostate cancer cells to extracellular matrix, the potential role of TGase-core domain.

Authors:  Wen G Jiang; Lin Ye; Andrew J Sanders; Fiona Ruge; Howard G Kynaston; Richard J Ablin; Malcolm D Mason
Journal:  J Transl Med       Date:  2013-10-25       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.